Navigation Links
Mylan Receives Approval for Nabumetone Tablets
Date:7/14/2010

PITTSBURGH, July 14 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nabumetone Tablets USP, 500 mg and 750 mg. The product was determined to be bioequivalent and, therefore, therapeutically equivalent to Nabumetone Tablets, a treatment for osteoarthritis and rheumatoid arthritis. The product will be distributed by Mylan Pharmaceuticals Inc.

Nabumetone Tablets had U.S. sales of approximately $68 million for the 12 months ending March 31, 2010, according to IMS Health.

Currently, Mylan has 134 ANDAs pending FDA approval representing $93.8 billion in annual brand sales, according to IMS Health. Thirty-nine of these pending ANDAs are potential first-to-file opportunities, representing $20.2 billion in annual brand sales, for the 12 months ending Dec. 31, 2009 according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Schedules Second Quarter 2010 Financial Results Conference Call and Live Webcast
2. Mylan Receives Approval for Generic Version of Arimidex® Tablets
3. Mylan Receives Approval for Generic Version of Zocor® Tablets
4. Mylan Receives Approval for Hydroxyzine Hydrochloride Tablets
5. Mylan Receives Approval for Generic Version of Neurontin® Tablets
6. Mylan Receives Approval for Generic Version of Valtrex®
7. Mylan Launches Temazepam Capsules USP, 7.5 mg
8. Mylan Announces Completion of Senior Notes Offering
9. Mylan Announces Upsizing and Pricing of Senior Notes
10. Mylan Announces Proposed Senior Notes Private Placement
11. Mylan Receives Approval for Generic Version of Zyban(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... , June 7, 2017 Endo International plc ... 7, 2017, the Hon. Joseph R. Goodwin , ... West Virginia , entered a case ... Pelvic Repair System Products Liability Litigation (the "MDL") that ... cases to provide expert disclosures on specific causation within ...
(Date:6/5/2017)... , June 5, 2017 The ... brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded ... Cincinnati Enquirer . Results are based on an ... in organizational health and workplace improvement. The survey measures several ... ...
(Date:6/2/2017)... 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical ... new findings demonstrating positive biochemical outcomes related to more ... The data will be presented at the ERA-EDTA Congress ... Spain . The research was ... Network in Europe (KIHDNEy) ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... June 26, 2017 , ... Dr. Martin Bastuba, ... in collaboration with the Fertility Center of California, is pleased to announce the ... sperm aspiration) and TESA (percutaneous testicular sperm extraction). These minimally invasive treatments are ...
(Date:6/26/2017)... ... June 26, 2017 , ... If the devil is ... of red these days. According to recent estimates, 75 – 80% of the ... errors(1). Some studies point to Electronic Health Records (EHR) with automated features designed ...
(Date:6/25/2017)... ... June 25, 2017 , ... Republicans in the United ... replace Obamacare, called the Better Care Reconciliation Act. It differs significantly from the American ... need to be reconciled in committee, or the House will have to take up ...
(Date:6/24/2017)... ... June 24, 2017 , ... Genes ... for medications in select Florida and Texas doctors' offices and clinics. This breakthrough ... application of genetic testing recognizes the role genes play in determining an individual's ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... Network today announced the launch of Care Management Alerts and Dashboards, an innovative ... patients throughout Rhode Island. , RIQI’s Care Management Alerts and Dashboards provide near ...
Breaking Medicine News(10 mins):